Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman
{"title":"From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma.","authors":"Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman","doi":"10.36849/JDD.8199","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.</p><p><strong>Methods: </strong>This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).</p><p><strong>Results: </strong>Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.</p><p><strong>Conclusion: </strong>Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.
Methods: This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).
Results: Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.
Conclusion: Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.
期刊介绍:
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.